Turning Point Therapeutics Inc.

Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global

Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves

BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more

Eleven label expansions also among committee’s November recommendations

Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers

As VC-backed start-ups continue to watch and wait for their IPO window, a large syndicate backs an oncology start-up with aspirations to go public

Plus new rounds for Kenai, BlossomHill and more

The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff

Early 2024 dealmaking activity also included Roche-MOMA, Avenzo-Allorion, AbbVie-Umoja and Boehringer-3T

Plus: CCO Olinger leaving Amylyx and updates from Coherus, Compass and NanoMosaic